GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition

• Egile Nagusiak: Eloïne Bestion (Egilea), Zuzana Macek Jilkova (Egilea), Jean-Louis Mège (Egilea), Marie Novello (Egilea), Keerthi Kurma (Egilea), Seyedeh Tayebeh Ahmad Pour (Egilea), Gilles Lalmanach (Egilea), Lise Vanderlynden (Egilea), Lionel Fizanne (Egilea), Firas Bassissi (Egilea), Madani Rachid (Egilea), Jennifer Tracz (Egilea), Jérôme Boursier (Egilea), Jérôme Courcambeck (Egilea), Cindy Serdjebi (Egilea), Christelle Ansaldi (Egilea), Thomas Decaens (Egilea), Philippe Halfon (Egilea), Sonia Brun (Egilea)
• Formatua: Liburua
• Argitaratua: SAGE Publishing, 2020-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Hepatic fibrosis is the result of chronic liver injury that can progress to cirrhosis and lead to liver failure. Nevertheless, there are no anti-fibrotic drugs licensed for human use. Here, we investigated the anti-fibrotic activity of GNS561, a new lysosomotropic molecule with high live...